Video: Experts predict the future of Big Data at #JPM16

Storing, analyzing and managing the big data sets that are being created around genomics for drug development has created challenges for the biopharma industry. Some leaders in the field, including Google and the Broad Institute in Cambridge, MA, have been battering down some of these barriers, making it possible to explore the data for clues about new drug development opportunities. FierceBiotech has gathered the leaders in the field to discuss what's being done with Big Data, how that relates to large and small developers alike and where this important sector is headed in the next 10 years.

FierceBiotech Editor-in-Chief John Carroll is joined by a distinguished panel of experts including David Glazer, engineering director at Google; Anthony Philippakis, chief data officer at the Broad Institute; Atul Butte, director of the UCSF Institute for Computational Health Sciences; Michael Pellini, president and CEO of Foundation Medicine; and Matthew Trunnell, vice president and CIO of the Fred Hutchinson Cancer Research Center.

Suggested Articles

Despite the setback, Fulcrum hailed the data as “very encouraging,” zeroing in on results from a pre-specified sensitivity analysis to make its case.

Bayer has struck a $425 million upfront deal to buy KaNDy in the belief its treatment for menopause-related hot flashes has blockbuster potential.

After its recent $4.8 billion buyout of gene therapy specialist Spark Therapeutics, Roche is now handing over one of its execs as its CMO.